Business Wire

New Ferring and Aché Laboratórios Farmacêuticos Facility Opens to Optimise Drug Delivery Using Nanotechnology

Jaa

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo, Brazil. Focused exclusively on nanotechnology research and development, the centre forms the first phase in a long term collaboration to optimise patient care through enhanced drug delivery systems and product solutions.

The Nanotechnology Innovation Laboratory Enterprise (NILE) centre and associated research programme will explore nanotechnology to advance the delivery characteristics of existing medicines, create novel devices and find new formulations for poorly soluble drugs. For example, for patients who currently receive treatment by injection, this new technology has the potential to transform their ongoing care with new oral options. Researchers will investigate how nanotechnology might improve the bioavailability, efficacy and safety profile of oral medicines, and alleviate any unwanted toxicity resulting from non-specific distribution.

Initial research projects will utilise each company’s therapeutic strengths. Ferring will provide expertise on peptides and proteins in reproductive medicine and women’s health, gastroenterology and urology, and Aché will provide knowledge on how to expedite the development of new therapeutic entities with different technical properties.

“Using nanotechnology to administer peptide and protein-based medicines orally could be a significant step forward for the ease of delivery for this important class of drugs,” said Alan Harris, Senior Vice President, R&D, Ferring Pharmaceuticals. “Ferring’s pioneering work in reproductive medicine and women’s health is devoted to providing next generation solutions that improve outcomes and better serve the needs of our patients. If we can provide patients with more convenient dosing, we will help to improve adherence and ensure that patients receive the greatest benefit from treatment.”

“In recent years, considerable investment has been made in Brazil to harness the potential of nanotechnology. Our established strength in using radical innovation to create new assets, whether synthetic, herbal, biologicals or nutraceuticals, combined with the rich source of natural compounds existing within Brazilian biodiversity, places us in a unique position to lead future cutting-edge science,” said Stephani Saverio, head of Innovation of Aché. “Nanotechnology has huge potential to address the challenges associated with today’s drug delivery systems and to optimise future care.”

The NILE centre is anticipated to be a global hub for future drug discovery and development. The inauguration ceremony brought together leading experts from the field of nanotechnology as well as dignitaries from the Ministry of Health of Brazil and government officials.

- Ends -

About Nanotechnology
Nanotechnology is a branch of technology focused on understanding and controlling matter at the very smallest scales. At nanoscale, properties can be very different when compared to those with which we are familiar. Such properties mean that nanotechnology has the potential to optimise current drug delivery technologies, and offers many opportunities to create new drug delivery systems, formulations for poorly soluble drugs and novel devices. In addition to the potential advantages of enhancing systemic administration, nanoparticulate drug delivery systems can also be used for site-specific delivery, thus alleviating unwanted toxicity due to nonspecific distribution, helping to improve patient compliance and provide favourable clinical outcomes. Nanotechnology platforms will help in the development of advanced drug-delivery systems to decrease the failure rate of new active pharmaceutical ingredients (APIs), bio-therapeutic agents and vaccines caused by poor absorption, or distribution, significant drug toxicity, and rapid metabolism or excretion.

About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.

Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews

About Aché Laboratórios Farmacêuticos
Aché is a 100% Brazilian company with more than 50 years of operation in the pharmaceutical market with the objective of bringing more life to the persons, wherever they are. It has three industrial sites: Guarulhos (SP), São Paulo (SP), and Londrina (PR), and participation in Melcon do Brasil, and Bionovis, a Brazilian joint venture dedicated to research and development of biotechnology medicines. It employs 4,600 people and has one of the largest demand and sales generation forces in the pharmaceutical sector in Brazil. In order to meet the needs of healthcare professionals and consumers, Aché offers a portfolio of 326 brands in 804 submissions for prescription, generic and OTC (non-prescription) drugs, and it also acts in the segments of skin cosmetics, nutraceuticals, probiotic and biological segments. Ache´s focus on innovation has been developing attractive products currently present in 20 countries of the Americas, Africa, and Asia. Ache´s innovative products are being developed for registration in the world´s most regulated markets. To know more about Aché, please visit www.ache.com.br.

Contact information

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
or
For Aché Laboratórios Farmacêuticos
Press Information:
CDI Corporative Communication
Renata Lopes
+55 (11) 3817-7994
renata.lopes@cdicom.com.br
or
Flavia Tavares
+55 (11) 3817-7914
flavia@cdicom.com.br
or
Cláudia Santos
+55 (11) 3817-7925
claudia@cdicom.com.br

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 12:00Tiedote

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 10:00Tiedote

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction15.6.2018 10:00Tiedote

Philip Morris International (PMI) (NYSE:PM) announces today the positive results from a new clinical study on IQOS, the company’s most advanced smoke-free product. The Exposure Response Study (ERS) measured the biological response of people who switch to IQOS for six months compared with continued smoking. The study met its primary objective, demonstrating that after six months, eight measures of biological response (the primary clinical risk endpoints) improved in those who switched to IQOS. PMI’s Scientific Assessment Program has rigorously tested IQOS over more than 7 years and supports that switching to our most advanced smoke-free product is likely to present less risk of harm than continuing to use cigarettes. Numerous aerosol chemistry and physics measurements demonstrate that IQOS aerosol contains an average of 90-95% lower levels of harmful constituents. Our results support that these reduced emissions translate to reduced toxicity in the laboratory and to reduced exposure in

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme